Archive

Neovasc Reducer™ Granted Breakthrough Device Designation from FDA

NASDAQ, TSX: NVCN VANCOUVER, Oct. 10, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of...

Read More

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

NASDAQ, TSX: NVCN VANCOUVER, Oct. 9, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of...

Read More

Neovasc’s Tiara and Reducer to be Featured at TCT 2018 Conference

NASDAQ, TSX: NVCN VANCOUVER, Sept. 20, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...

Read More

Neovasc Announces 100th Patient to Receive Reducer Therapy in Germany

NASDAQ, TSX: NVCN VANCOUVER, Sept. 19, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of...

Read More

Neovasc Announces Effective Date of Share Consolidation

NASDAQ, TSX: NVCN VANCOUVER, Sept. 18, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina,...

Read More